Bicara Therapeutics Inc. (BCAX) · INSIDERData sourcesSEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago
Public companyBicara Therapeutics Inc.
BCAXCIK 0002023658
Price$9.98
1 year-31.5%
Disclosed transactions50
Buys / sells0 / 16
Max Insider Score30
Connections with evidence5
BCAX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 3 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 9,200 sh | Apr 21, 2026 | Apr 22, 2026 |
| 13 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $212K 9,200 sh | Apr 21, 2026 | Apr 22, 2026 traded Apr 21, 2026 | +1d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $35K 9,200 sh | Apr 21, 2026 | Apr 22, 2026 traded Apr 21, 2026 | +1d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $28K 7,454 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $36K 8,226 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $39K 7,080 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $57K 15.0K sh | Apr 20, 2026 | Apr 20, 2026 traded Apr 20, 2026 | +0d | SEC Form 4 | |
| 12 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $354K 15.0K sh | Apr 20, 2026 | Apr 20, 2026 traded Apr 20, 2026 | +0d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 15.0K sh | Apr 20, 2026 | Apr 20, 2026 traded Apr 20, 2026 | +0d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 7,454 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 8,226 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 0 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 7,080 sh | Apr 16, 2026 | Apr 20, 2026 traded Apr 16, 2026 | +4d | SEC Form 4 | |
| 8 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $104K 5,500 sh | Mar 25, 2026 | Mar 26, 2026 traded Mar 25, 2026 | +1d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $21K 5,500 sh | Mar 25, 2026 | Mar 26, 2026 traded Mar 25, 2026 | +1d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 5,500 sh | Mar 25, 2026 | Mar 26, 2026 traded Mar 25, 2026 | +1d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 1,882 sh | Jan 22, 2026 | Jan 26, 2026 traded Jan 22, 2026 | +4d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $7,132 1,882 sh | Jan 22, 2026 | Jan 26, 2026 traded Jan 22, 2026 | +4d | SEC Form 4 | |
| 9 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $69K 3,828 sh | Jan 22, 2026 | Jan 26, 2026 traded Jan 22, 2026 | +4d | SEC Form 4 | |
| 6 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $34K 1,882 sh | Jan 22, 2026 | Jan 26, 2026 traded Jan 22, 2026 | +4d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 9,200 sh | Dec 22, 2025 | Dec 23, 2025 traded Dec 22, 2025 | +1d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $35K 9,200 sh | Dec 22, 2025 | Dec 23, 2025 traded Dec 22, 2025 | +1d | SEC Form 4 | |
| 13 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $168K 9,200 sh | Dec 22, 2025 | Dec 23, 2025 traded Dec 22, 2025 | +1d | SEC Form 4 | |
| 12 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise | M | $161K 29.5K sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
| 9 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise | M | — 29.5K sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
| 0 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 8,000 sh | Dec 15, 2025 | Dec 16, 2025 traded Dec 15, 2025 | +1d | SEC Form 4 | |
| 9 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $149K 8,000 sh | Dec 15, 2025 | Dec 16, 2025 traded Dec 15, 2025 | +1d | SEC Form 4 | |
| 9 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $84K 4,500 sh | Dec 15, 2025 | Dec 16, 2025 traded Dec 15, 2025 | +1d | SEC Form 4 | |
| 0 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $30K 8,000 sh | Dec 15, 2025 | Dec 16, 2025 traded Dec 15, 2025 | +1d | SEC Form 4 | |
| 30 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $776K 41.2K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 3 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 8,000 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 0 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $30K 8,000 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 16 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $17K 906 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
| 20 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $11K 605 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 3 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 17.8K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 6 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $156K 41.2K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 23 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $144K 8,000 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 5,500 sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 27 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $101K 5,500 sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 2 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $67K 17.8K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 23 | CRCohlhepp RyanDirector, President and COO | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $81K 4,500 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 7 | MCMazumdar ClaireDirector, Chief Executive Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 41.2K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 3 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $21K 5,500 sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 23 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $87K 4,594 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $3,434 906 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 4,594 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 906 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $2,293 605 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 26 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Open-market sale · 10b5-1 plan | SELL | $330K 17.8K sh | Nov 24, 2025 | Nov 25, 2025 traded Nov 24, 2025 | +1d | SEC Form 4 | |
| 0 | HIHyep IvanChief Financial Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | — 605 sh | Nov 21, 2025 | Nov 25, 2025 traded Nov 21, 2025 | +4d | SEC Form 4 | |
| 0 | RDRaben DavidChief Medical Officer | BCAXBicara Therapeutics Inc. Option exercise · 10b5-1 plan | M | $17K 4,594 sh | Nov 25, 2025 | Nov 25, 2025 traded Nov 25, 2025 | +0d | SEC Form 4 | |
Chief Financial Officer · Nov 25, 2025